Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Nuclear pore complex-interacting protein family member A2 (NPIPA2) is a human protein localized at the nuclear membrane and predicted to be part of the nuclear pore complex. It is thought to function in mRNA and protein transport across the nuclear envelope, facilitating nucleocytoplasmic transport. The protein is not well characterized in the literature, and its specific roles, disease involvement, and therapeutic relevance remain largely unexamined. There is no evidence it serves as a conventional therapeutic target or as a biomarker, and no drugs are associated with NPIPA2. The gene is referenced in several genomic databases, confirming its sequence and standard aliases, but no clear molecular family fit (such as receptor, enzyme, etc.) is provided. Disease associations in available sources are primarily computational or text-mined and do not establish causality or clinical relevance.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Nuclear pore complex-interacting protein family member A2 (NPIPA2).